Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS)
The invention concerns the use of phosphatidylserine (PS), lyso-phosphatidylserine or/and a physiologically acceptable salt thereof for the treatment of the attention deficit syndrome (ADHS) in small daily doses over a longer time period and in larger daily doses over a short period as well as in co...
Gespeichert in:
Hauptverfasser: | , |
---|---|
Format: | Patent |
Sprache: | eng |
Online-Zugang: | Volltext bestellen |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | |
---|---|
container_issue | |
container_start_page | |
container_title | |
container_volume | |
creator | Jäger, Ralf Bökenkamp, Dirk |
description | The invention concerns the use of phosphatidylserine (PS), lyso-phosphatidylserine or/and a physiologically acceptable salt thereof for the treatment of the attention deficit syndrome (ADHS) in small daily doses over a longer time period and in larger daily doses over a short period as well as in combination with suitable additives selected from the group comprising antioxidants, essential fatty acids, mineral substances, amino acids, mood-lifters or/and phospholipids. In this connection it is preferred to carry out the administration to probands aged 2 to 20 years preferably 3 to 10 years whereby the phosphatidylserine as well as the additives are used in solid and also in liquid formulations. Due to its positive properties phosphatidyl-serine is in particular suitable as a therapeutic agent or food supplement in connection with ADHS. The good tolerance of phosphatidylserine even in high doses and over a longer supplementation period and the excellent compliance should also be stressed. |
format | Patent |
fullrecord | <record><control><sourceid>uspatents_EFH</sourceid><recordid>TN_cdi_uspatents_grants_08129360</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>08129360</sourcerecordid><originalsourceid>FETCH-uspatents_grants_081293603</originalsourceid><addsrcrecordid>eNrjZAgPLcnMyaxKLMnMz1PIT1MoyMgvLsgAclMqc4pTizLzUhUy8xRKMlIVSopSE0tyU_NKQMoSS0qALJCelNS0zOTMEoXiyryUovzcVAUNRxePYE0eBta0RKAJvFCam0HBzTXE2UO3tLggEaS3OD69KBFEGVgYGlkamxkYE6EEAEThOsc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS)</title><source>USPTO Issued Patents</source><creator>Jäger, Ralf ; Bökenkamp, Dirk</creator><creatorcontrib>Jäger, Ralf ; Bökenkamp, Dirk ; Cargill Texturizing Solutions Deutschland GmbH & Co., KG</creatorcontrib><description>The invention concerns the use of phosphatidylserine (PS), lyso-phosphatidylserine or/and a physiologically acceptable salt thereof for the treatment of the attention deficit syndrome (ADHS) in small daily doses over a longer time period and in larger daily doses over a short period as well as in combination with suitable additives selected from the group comprising antioxidants, essential fatty acids, mineral substances, amino acids, mood-lifters or/and phospholipids. In this connection it is preferred to carry out the administration to probands aged 2 to 20 years preferably 3 to 10 years whereby the phosphatidylserine as well as the additives are used in solid and also in liquid formulations. Due to its positive properties phosphatidyl-serine is in particular suitable as a therapeutic agent or food supplement in connection with ADHS. The good tolerance of phosphatidylserine even in high doses and over a longer supplementation period and the excellent compliance should also be stressed.</description><language>eng</language><creationdate>2012</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8129360$$EPDF$$P50$$Guspatents$$Hfree_for_read</linktopdf><link.rule.ids>230,308,780,802,885,64039</link.rule.ids><linktorsrc>$$Uhttps://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/8129360$$EView_record_in_USPTO$$FView_record_in_$$GUSPTO$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>Jäger, Ralf</creatorcontrib><creatorcontrib>Bökenkamp, Dirk</creatorcontrib><creatorcontrib>Cargill Texturizing Solutions Deutschland GmbH & Co., KG</creatorcontrib><title>Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS)</title><description>The invention concerns the use of phosphatidylserine (PS), lyso-phosphatidylserine or/and a physiologically acceptable salt thereof for the treatment of the attention deficit syndrome (ADHS) in small daily doses over a longer time period and in larger daily doses over a short period as well as in combination with suitable additives selected from the group comprising antioxidants, essential fatty acids, mineral substances, amino acids, mood-lifters or/and phospholipids. In this connection it is preferred to carry out the administration to probands aged 2 to 20 years preferably 3 to 10 years whereby the phosphatidylserine as well as the additives are used in solid and also in liquid formulations. Due to its positive properties phosphatidyl-serine is in particular suitable as a therapeutic agent or food supplement in connection with ADHS. The good tolerance of phosphatidylserine even in high doses and over a longer supplementation period and the excellent compliance should also be stressed.</description><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2012</creationdate><recordtype>patent</recordtype><sourceid>EFH</sourceid><recordid>eNrjZAgPLcnMyaxKLMnMz1PIT1MoyMgvLsgAclMqc4pTizLzUhUy8xRKMlIVSopSE0tyU_NKQMoSS0qALJCelNS0zOTMEoXiyryUovzcVAUNRxePYE0eBta0RKAJvFCam0HBzTXE2UO3tLggEaS3OD69KBFEGVgYGlkamxkYE6EEAEThOsc</recordid><startdate>20120306</startdate><enddate>20120306</enddate><creator>Jäger, Ralf</creator><creator>Bökenkamp, Dirk</creator><scope>EFH</scope></search><sort><creationdate>20120306</creationdate><title>Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS)</title><author>Jäger, Ralf ; Bökenkamp, Dirk</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-uspatents_grants_081293603</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng</language><creationdate>2012</creationdate><toplevel>online_resources</toplevel><creatorcontrib>Jäger, Ralf</creatorcontrib><creatorcontrib>Bökenkamp, Dirk</creatorcontrib><creatorcontrib>Cargill Texturizing Solutions Deutschland GmbH & Co., KG</creatorcontrib><collection>USPTO Issued Patents</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>Jäger, Ralf</au><au>Bökenkamp, Dirk</au><aucorp>Cargill Texturizing Solutions Deutschland GmbH & Co., KG</aucorp><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS)</title><date>2012-03-06</date><risdate>2012</risdate><abstract>The invention concerns the use of phosphatidylserine (PS), lyso-phosphatidylserine or/and a physiologically acceptable salt thereof for the treatment of the attention deficit syndrome (ADHS) in small daily doses over a longer time period and in larger daily doses over a short period as well as in combination with suitable additives selected from the group comprising antioxidants, essential fatty acids, mineral substances, amino acids, mood-lifters or/and phospholipids. In this connection it is preferred to carry out the administration to probands aged 2 to 20 years preferably 3 to 10 years whereby the phosphatidylserine as well as the additives are used in solid and also in liquid formulations. Due to its positive properties phosphatidyl-serine is in particular suitable as a therapeutic agent or food supplement in connection with ADHS. The good tolerance of phosphatidylserine even in high doses and over a longer supplementation period and the excellent compliance should also be stressed.</abstract><oa>free_for_read</oa></addata></record> |
fulltext | fulltext_linktorsrc |
identifier | |
ispartof | |
issn | |
language | eng |
recordid | cdi_uspatents_grants_08129360 |
source | USPTO Issued Patents |
title | Utilization of phosphatidylserine in the treatment of attention deficit syndrome (ADHS) |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-05T07%3A50%3A59IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-uspatents_EFH&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=J%C3%A4ger,%20Ralf&rft.aucorp=Cargill%20Texturizing%20Solutions%20Deutschland%20GmbH%20&%20Co.,%20KG&rft.date=2012-03-06&rft_id=info:doi/&rft_dat=%3Cuspatents_EFH%3E08129360%3C/uspatents_EFH%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |